Related Experiment Videos

Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

I M Keularts1, S Béguin, C de Zwaan

  • 1Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, The Netherlands.

Thrombosis and Haemostasis
|October 6, 1998
PubMed

Insights

Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors like MK383 reduce thrombin generation by limiting procoagulant phospholipid exposure on platelets. This effect mirrors heparin

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Thrombin generation is crucial for hemostasis.
  • Platelets play a key role in thrombin generation through procoagulant activity.
  • Platelet activation is mediated by various factors, including thrombin itself.

Purpose of the Study:

  • To investigate the effect of the GPIIb/IIIa inhibitor MK383 on thrombin generation.
  • To compare the mechanism of MK383 with heparin in inhibiting thrombin generation.
  • To elucidate the role of platelet procoagulant phospholipid exposure in thrombin generation.

Main Methods:

  • In vitro study using platelet-rich plasma.
  • Infusion of GPIIb/IIIa inhibitor MK383.
  • Measurement of thrombin generation.
  • Comparison with heparin infusion.

Main Results:

  • MK383 significantly inhibited thrombin generation in platelet-rich plasma.
  • The inhibition by MK383 was attributed to interference with platelet procoagulant phospholipid exposure.
  • Heparin also inhibited thrombin generation, likely by enhancing antithrombin activity and reducing platelet activation.

Conclusions:

  • GPIIb/IIIa inhibitors can effectively reduce thrombin generation by targeting platelet procoagulant function.
  • Platelet-derived procoagulant microparticles are important in thrombin generation.
  • Understanding these mechanisms can inform antithrombotic strategies.

Related Concept Videos